Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $309 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.